Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.

U.S. drug regulators have approved expanding the use of Eli Lilly’s diabetes drug Mounjaro to include the treatment of obesity.

The Food and Drug Administration’s decision Wednesday furthers the rapid rise of Mounjaro—and similar-acting therapies Ozempic and Wegovy from Novo Nordisk—that have in a matter of months reshaped the treatment of obesity and doctors’ understanding of its roots.